Mindanao State University – Iligan Institute of Technology Student: SALIMBAGAT, CHRISTINE.

P Section: 262
COLLEGE OF NURSING

PHARMACOLOGY DRUG STUDY

Brand Name: Betapace Generic Name: Sotalol hydrochloride Drug Classification: Antiarrhythmics (class III)

Dosage, Route & Frequency

Pre Drug Drug-Drug & Drug-Food Side Effects
Indications Contraindications Adverse Reactions (By System)
Recommended scri Action Interactions (By System)
bed
Ventricular Arrhythmias (Betapace) Has both Drug: Antagonizes the Management Hypersensitivity to sotalol; CNS: headache, CV: AV block, hypotension,
Adult: PO Initial dose of 80 mg b.i.d. or class II and effects of BETA of life- bronchial asthma, sinus dizziness, sleep aggravation of CHF, although the
160 mg q.d. taken prior to meals, may class III AGONISTS. Amiodarone ma threatening bradycardia, sick sinus problems incidence of heart failure may be
increase every 3–4 d in 40–160 mg antiarrhyt y lead to symptomatic ventricular syndrome; second and third (insomnia), lower than for other beta-
increments (most patients respond to hmic bradycardia and sinus arrhythmias. degree heart block, long QT GI:, diarrhea, blockers, life-threatening ventricular
240–320 mg/d in 2 or 3 divided doses, properties. arrest. The hypoglycemic Betapace AF: syndrome, cardiogenic shock, nausea, arrhythmias, including
doses >640 mg/d have not been Slows effects of ORAL Maintenance uncontrolled CHF; chronic vomiting, polymorphous ventricular
studied) heart rate, HYPOGLYCEMIC of normal sinus bronchitis, emphysema; upset stomach tachycardia or torsades de
Renal Impairment decreases AGENTS may be rhythm in hypokalemia <4 mEq/L; Body as a Whole: pointes, bradycardia, dyspnea, chest
Clcr >60 mL/min: q12h; 30–60 mL/min: AV nodal potentiated. May cause patients with creatinine clearance of <40 fatigue, pain, palpitation, bleeding (<2%). 
q24h; 10–30 mL/min: q36–48h; <10 conductio resistance to epinephrine in highly mL/min; lactation. weakness, CNS: Headache, fatigue,
mL/min: Individualize carefully n, and anaphylactic reactions. symptomatic Cautious Use tiredness, pain in dizziness, weakness, lethargy,
Atrial Fibrillation/flutter (Betapace AF) increases Should be used with atrial CHF, electrolyte disturbances, your arms or legs depression, lassitude. 
Adult: PO Initial dose of 80 mg b.i.d., AV nodal caution with fibrillation/atri recent MI, diabetes, sick sinus CV: slow heart rate, GI: Nausea, vomiting, diarrhea,
may increase every 3–4 d (max: 240 refractorin other ANTIARRHYTHMIC al flutter rhythm, renal impairment; chest pain, dyspepsia, dry mouth. 
mg/d in 1–2 divided doses) ess. AGENTS.  (AF/AFL) who pregnancy (category B); palpitations,, Urogenital: Impotence, decreased
Renal Impairment Food: absorption are currently in concomitant use of drugs which sleep problems libido. 
Clcr >60 mL/min: q12h; 40–60 mL/min: of sotalol may be reduced sinus rhythm. prolong the QT segment, and (insomnia), Metabolic: Hyperglycemia. 
q24h; <40 mL/min contraindicated by food, antiarrhythmic drugs; excessive Urogenital: Special Senses: Visual disturbances. 
especially milk and MILK diarrhea, or profuse sweating. decreased sexual Respiratory: Respiratory complaints.
PRODUCTS. ability. Skin: Rash.
Responsibilities in the Nursing Process (ADPIE) Responsibilities in the Nursing Process (ADPIE)
A - ● Monitor ECG prior to and periodically during therapy. May cause life-threatening Teaching)
ventricular tachycardia associated with QT interval prolongation. Do not initiate sotalol P - Control arrhythmias without appearance of detrimental side effects.
therapy if baseline QTc is longer than 450 ms. If QT interval becomes 500 ms, reduce I – : ●Calculate creatinine clearance prior to dosing. ● Do not confuse sotalol with Sudafed (pseudoephedrine). ●
dose, prolong duration of infusion, or discontinue therapy ●Monitor intake and output Patients should be hospitalized and monitored for arrhythmias for at least 3 days during initiation of therapy and
ratios and daily weight. ●Assess patient routinely for evidence of fluid overload dose increases. PO: Take apical pulse prior to administering. If 50 bpm or if arrhythmia occurs, withhold
(peripheral edema, dyspnea, rales/crackles, fatigue, weight gain, jugular venous medication and notify health care professional. ● Administer on an empty stomach, 1 hr b
distention). E - Controlled arrhythmias without appearance of detrimental side effects.
D - ●Decreased cardiac output (Side Effects) ●Noncompliance (Patient/Family